论文部分内容阅读
目的分析肾透明细胞癌组织中受体酪氨酸激酶Eph A3的表达及临床意义。方法以2010年1月-2015年12月医院病理科确诊的68例肾透明细胞癌患者石蜡组织标本为研究对象(实验组);另择取同期医院收治的68例肾脏肿瘤患者为对照组,取患者肿瘤旁5 cm以上正常肾小管细胞标本为对照。采用免疫组化法对全部细胞标本中受体酪氨酸激酶Eph A3的表达进行检测,观察Eph A3在2组患者中表达的差异性,分析Eph A3与肾透明细胞癌患者临床病理特征关系。结果 Eph A3阳性表达于胞质,实验组Eph A3表达阳性率(27.9%)低于对照组Eph A3表达阳性率(100.0%)(P<0.05)。实验组ccRCC组织中Eph A3表达高表达48例(70.6%),低表达20例(29.4%),Eph A3高表达患者与TNM分期、肿瘤分化及有无转移有关(P<0.05)。结论 Eph A3高表达与肾透明细胞癌的生长和转移存在关联,可能成为肾透明细胞癌预后标志物,在肾透明细胞癌临床诊治中发挥重要作用,具备深入研究价值。
Objective To analyze the expression of receptor tyrosine kinase Eph A3 in renal clear cell carcinoma and its clinical significance. Methods Sixty-eight paraffin-embedded specimens of renal cell carcinoma from January 2010 to December 2015 were selected as the experimental group (experimental group). Sixty-eight patients with renal tumors admitted to the same hospital at the same period were selected as the control group, Take samples of normal tubular cells above 5 cm beside the tumor as control. Immunohistochemistry was used to detect the expression of Eph A3, a receptor tyrosine kinase in all cell samples. The difference of expression of Eph A3 in two groups of patients was observed. The relationship between Eph A3 and the clinicopathological features of renal clear cell carcinoma was analyzed. Results The positive expression of EphA3 in the cytoplasm was lower in the experimental group than that in the control group (27.9%, 100.0%) (P <0.05). The expression of EphA3 was high in 48 (70.6%) and 20 (29.4%) of the patients in the experimental group. The expression of EphA3 was correlated with TNM stage, tumor differentiation and metastasis (P <0.05). Conclusion The high expression of Eph A3 is associated with the growth and metastasis of renal clear cell carcinoma and may be a prognostic marker of clear cell renal cell carcinoma. It plays an important role in the clinical diagnosis and treatment of renal clear cell carcinoma and is of great value.